Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205).
CONCLUSION: This regimen demonstrated promising activity. Toxicity was significant, with seven study-related deaths leading to closure after stage 1. All postoperative deaths were due to ARDS. This regimen is not recommended.
IMPLICATIONS FOR PRACTICE: Esophageal cancer is a disease with a high death rate. The current treatment involves giving chemotherapy plus radiation followed by surgery, but this cures only a quarter of patients. In order to improve survival, better treatments are needed. This trial evaluated the addition of a novel drug, cetuximab, to chemotherapy plus radiation. Unfortunately, the side effects were too great and the study was stopped early.
PMID: 31227647 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Gibson MK, Catalano P, Kleinberg LR, Staley CA, Montgomery EA, Jimeno A, Song WF, Mulcahy MF, Leichman LP, Benson AB Tags: Oncologist Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Eloxatin | Erbitux | Esophagectomy | Esophagus Cancer | Intensity-Modulated Radiation Therapy | Pulmonary Thromboembolism | Respiratory Medicine | Study | Taxotere | Toxicology